12-Year-Old Boy Begins Life-Changing Treatment for Duchenne Muscular Dystrophy
Dad’s warning after son, 12, finally gets 'life-changing' Duchenne drug
Image: Mirror
Ben Clarke, a 12-year-old boy from Sonning Common, Oxfordshire, has started a groundbreaking treatment for Duchenne Muscular Dystrophy (DMD) after years of campaigning. While his family celebrates this milestone, they stress the urgency for access to the drug, givinostat, for non-ambulant patients who remain without treatment options.
- 01Ben Clarke was diagnosed with Duchenne Muscular Dystrophy (DMD) in 2017 and has begun treatment with givinostat, which aims to slow muscle degeneration.
- 02The treatment is currently only approved for boys who can walk, leaving many non-ambulant patients without access.
- 03Ben's father, Alex Clarke, has been an advocate for access to the drug, highlighting the emotional and physical challenges faced by families with DMD.
- 04The campaign for givinostat's approval involved over a year of advocacy, reflecting the difficulties in accessing treatments for rare diseases.
- 05Duchenne UK emphasizes the need for reform in the approval process to ensure timely access to medications for all patients with severe conditions.
Advertisement
In-Article Ad
Ben Clarke, a 12-year-old from Sonning Common, Oxfordshire, has begun a significant treatment for Duchenne Muscular Dystrophy (DMD) after years of uncertainty and campaigning. His family fought for access to givinostat, a drug approved through an early access program for ambulant boys. Ben's father, Alex Clarke, expressed joy at his son's progress but raised concerns about the lack of treatment options for non-ambulant boys, who remain without access to this potentially life-changing drug. The family campaigned alongside Duchenne UK, which highlighted that many families have been left behind during the lengthy approval process. Alex emphasized the emotional toll of watching his son's condition progress while advocating for necessary reforms to ensure that all patients, regardless of their mobility, can access effective treatments. He described the situation as a
Advertisement
In-Article Ad
The approval of givinostat for ambulant boys like Ben Clarke represents a significant step forward, but highlights the urgent need for access for non-ambulant patients.
Advertisement
In-Article Ad
Reader Poll
What do you think about the current access to treatments for rare diseases?
Connecting to poll...
Read the original article
Visit the source for the complete story.